Life Science Partners, a Dutch venture capital firm has invested €4 million in a €11.5 million series A financing round of ActoGeniX, a Belgian bio-pharmaceutical company.
The transaction was led by Life Science Partners and GIMV, a Dutch rival.
Life Sciences Partners also appointed of Martijn Kleijwegt as a non-executive director representing the firm on the supervisory board of ActoGeniX.
With this financing, ActoGeniX will focus on developing therapeutic products based on its TopAct technology, a proprietary delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals.
ActoGeniX products will address a broad range of diseases, such as gastrointestinal diseases, auto-immunity, allergy and metabolic disease.
The company’s lead product for the treatment of Crohn’s disease has already successfully been tested in patients.